Vivos Therapeutics VVOS Insider Ownership

Updated Oct 5, 2026

Over the trailing 12 months, VVOS insiders bought $1.81 million worth of shares (1.35Mn shares) in open-market trades, with no open-market sales.

• Among Vivos Therapeutics' insiders, Michael C. Skaff (10% owner) was the largest open-market buyer over the past 12 months, purchasing $1.81 million of stock (1.35Mn shares), most recently on March 31, 2026.
• Outside the open market, Vivos Therapeutics insiders received 250K shares in stock awards over the past 12 months.
• Business Quant data puts insider holdings in VVOS at 1.61Mn shares across insiders' latest Form 4 filings, or 9.09% of the 17.68Mn shares outstanding; that total is up 18.42% from 1.36Mn shares at the end of Q2 2026.
• By type of ownership, VVOS insiders hold 15.78% of their shares directly (253.54K shares) and 84.22% indirectly (1.35Mn shares).
• Business Quant counts 3 insiders with holdings in Vivos Therapeutics stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• VVOS's three largest insider shareholders, per their latest Form 4 filings, are Michael C. Skaff (10% owner, 1.35Mn shares), Bradford K. Amman (Principal Accounting Officer, 250.08K shares) and Ronald Kirk Huntsman (Chief Executive Officer, 3.46K shares).
• The largest insider, Michael C. Skaff, holds 84.22% of VVOS's insider total.
• Over the trailing 12 months, 4 insiders reported transactions in VVOS stock across 5 Form 4 filings.
• These insider figures for Vivos Therapeutics are based on Form 4 filings through September 18, 2026.